{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:35:24Z","timestamp":1790386524366,"version":"4.1.0"},"reference-count":130,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1080\/14712598.2020.1766021","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:41:45Z","timestamp":1588725705000},"page":"1347-1359","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs"],"prefix":"10.1080","volume":"20","author":[{"given":"Terapong","family":"Tantawichien","sequence":"first","affiliation":[{"name":"Chulalongkorn University","place":["Pathumwan, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Rupprecht","sequence":"additional","affiliation":[{"name":"LYSSA LLC","place":["Cumming, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"issue":"2","key":"e_1_3_4_3_1","article-title":"Four thousand years of concepts relating to rabies in animals and humans, its prevention and its cure","volume":"2","author":"Tarantola A.","year":"2017","unstructured":"Tarantola A. Four thousand years of concepts relating to rabies in animals and humans, its prevention and its cure. Trop Med Infect Dis. 2017;2(2):21.","journal-title":"Trop Med Infect Dis"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.91"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003709"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30245-5"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-019-04247-4"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-14741-9_6"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.16-0092"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48507-4"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aivir.2019.05.003"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1674580"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11060504"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.015"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001020"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2825"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-100114-055157"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000420"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35158-0"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24016"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0711"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2836"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006271"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6449a2"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2808"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003942"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.256.2.195"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2809"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.245.3.333"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1678-9946202062001"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2806"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002786"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107539"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006041"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/vex038"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.11.007"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/zph.12527"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.248.5.505"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2824"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.01.004"},{"key":"e_1_3_4_41_1","first-page":"297","article-title":"Rabies epidemiology: some ecological and evolutionary perspectives","volume":"187","author":"Wandeler AI","year":"1994","unstructured":"Wandeler AI, Nadin-Davis SA, Tinline RR, et al. Rabies epidemiology: some ecological and evolutionary perspectives. Curr Top Microbiol Immunol. 1994;187:297\u2013324.","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_4_42_1","first-page":"50","article-title":"Genotypic and phenotypic diversity of rabies virus variants involved in human rabies: implications for postexposure prophylaxis","volume":"3","author":"Dietzschold B","year":"2000","unstructured":"Dietzschold B, Morimoto K, Hooper DC, et al. Genotypic and phenotypic diversity of rabies virus variants involved in human rabies: implications for postexposure prophylaxis. J Hum Virol. 2000;3:50\u201357.","journal-title":"J Hum Virol"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004010050674"},{"key":"e_1_3_4_44_1","first-page":"181","article-title":"Rabies vaccinology and immunology","volume":"125","author":"Wandeler AI","year":"2006","unstructured":"Wandeler AI. Rabies vaccinology and immunology. Dev Biol (Basel). 2006;125:181\u2013184.","journal-title":"Dev Biol (Basel)"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-387040-7.00007-X"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/17460794.3.5.481"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.23.10908"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2830"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2015.4.1.68"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70340-1"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1994.1088"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1708-8305.2006.00097.x"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.37.2.2804"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.016"},{"key":"e_1_3_4_55_1","first-page":"384","article-title":"Guillain-Barre syndrome following antirabies Semple vaccine\u2013a report of six cases","volume":"49","author":"Udawat H","year":"2001","unstructured":"Udawat H, Chaudhary HR, Goyal RK, et al. Guillain-Barre syndrome following antirabies Semple vaccine\u2013a report of six cases. J Assoc Physicians India. 2001;49:384\u2013385.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_4_56_1","first-page":"41","article-title":"[Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab) in pre-exposure prophylaxis in humans]","volume":"132","author":"Favi M","year":"2004","unstructured":"Favi M, Yung V, Roos O, et al. [Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab) in pre-exposure prophylaxis in humans]. Rev Med Chil. 2004;132:41\u20136.Spanish.","journal-title":"Rev Med Chil"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004846"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.02.083"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1473765"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.9.12216"},{"key":"e_1_3_4_61_1","first-page":"144","article-title":"Testing a low-cost approach to giving eRIG for rabies PEP: ethical issues","volume":"4","author":"Cash RA","year":"2019","unstructured":"Cash RA. Testing a low-cost approach to giving eRIG for rabies PEP: ethical issues. Indian J Med Ethics. 2019;4:144\u2013145.","journal-title":"Indian J Med Ethics"},{"key":"e_1_3_4_62_1","first-page":"1","article-title":"Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2\/3 trial","volume":"24","author":"Matson MA","year":"2019","unstructured":"Matson MA, Schenker E, Stein M, et al. Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2\/3 trial. Hum Vaccin Immunother. 2019;24:1\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix791"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1140040"},{"issue":"2","key":"e_1_3_4_65_1","article-title":"New rabies vaccines for use in humans","volume":"7","author":"Ertl HCJ","year":"2019","unstructured":"Ertl HCJ. New rabies vaccines for use in humans. Vaccines (Basel). 2019;7(2)","journal-title":"Vaccines (Basel)"},{"key":"e_1_3_4_66_1","doi-asserted-by":"crossref","unstructured":"Rupprecht CE Freuling C Mani R Palacios C Sabeta C Ward M.A history of rabies - the foundation for global canine rabies elimination. 2020. In: Fooks AR Jackson AC editors. Rabies - scientific basis of the disease and its management. 4th ed. Academic Press: San Diego. pp. 1\u201342.","DOI":"10.1016\/B978-0-12-818705-0.00001-7"},{"issue":"1012","key":"e_1_3_4_67_1","first-page":"1","article-title":"WHO expert consultation on rabies. Third report","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO expert consultation on rabies. Third report. World Health Organ Tech Rep Ser. 2018;(1012):1\u2013183.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2019.06.005"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12393"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11100892"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.075"},{"issue":"3","key":"e_1_3_4_72_1","first-page":"1","article-title":"Human rabies prevention\u2013United States, 2008: recommendations of the advisory committee on immunization practices","volume":"57","author":"Advisory Committee on Immunization Practices","year":"2008","unstructured":"Advisory Committee on Immunization Practices. Human rabies prevention\u2013United States, 2008: recommendations of the advisory committee on immunization practices. MMWR. 2008;57(RR\u20133):1\u201328.","journal-title":"MMWR"},{"key":"e_1_3_4_73_1","unstructured":"World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO AEFI causality assessment classification. 2nd ed. 2018 [cited 2020 May 10]; Geneva (Switzerland). Available from: http:\/\/www.who.int\/vaccine_safety\/publications\/gvs_aefi\/en\/"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.09.069"},{"key":"e_1_3_4_75_1","first-page":"177","article-title":"An outbreak of post-vaccinal rabies (rage de laboratoire) in Fortaleza, Brazil, in 1960. Residual fixed virus as the etiological agent","volume":"33","author":"Par\u00e1 M","year":"1965","unstructured":"Par\u00e1 M. An outbreak of post-vaccinal rabies (rage de laboratoire) in Fortaleza, Brazil, in 1960. Residual fixed virus as the etiological agent. Bull World Health Organ. 1965;33:177\u2013182.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/0049475519852223"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1353\/lm.2019.0004"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2011.09.025"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000388"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/zph.12143"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X18817143"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1486354"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jtm.12228"},{"key":"e_1_3_4_84_1","first-page":"789","article-title":"Incidence of reactions to antirabies horse serum","volume":"68","author":"Hosty TS","year":"1953","unstructured":"Hosty TS, Hunter FR. Incidence of reactions to antirabies horse serum. 433021. 1953;68:789\u2013791.","journal-title":"433021"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1159\/000497053"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2015.09.003"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2011.02.018"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1244009"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.087"},{"key":"e_1_3_4_90_1","first-page":"80","article-title":"Is the skin sensitivity test required for administering equine rabies immunoglobulin?","volume":"24","author":"Sudarshan MK","year":"2011","unstructured":"Sudarshan MK, Ashwath Narayana DH, Ravish HS. Is the skin sensitivity test required for administering equine rabies immunoglobulin? Natl Med J India. 2011;24:80\u201382.","journal-title":"Natl Med J India"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114260"},{"key":"e_1_3_4_92_1","first-page":"48","article-title":"Rabies immune globulin (human) in the prevention of rabies","volume":"33","author":"Cabasso VJ","year":"1976","unstructured":"Cabasso VJ. Rabies immune globulin (human) in the prevention of rabies. Am J Hosp Pharm. 1976;33:48\u201351.","journal-title":"Am J Hosp Pharm"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.050"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000542"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.004"},{"key":"e_1_3_4_96_1","unstructured":"Zydus to launch novel biologic for rabies TwinrabTM. [cited 31 Jan 2020]. https:\/\/zyduscadila.com\/public\/pdf\/pressrelease\/Zydus%20to%20launch%20novel%20biologic%20for%20rabies_WHO.pdf"},{"key":"e_1_3_4_97_1","unstructured":"Rabishield rabies human monoclonal antibody. Serum institute of India PVT. LTD. [cited 2020 Jan 31]. <https:\/\/www.seruminstitute.com\/product_ind_rabishield.php>"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1048938"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1421074"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.072"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006340"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.10.103"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.041"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.10.054"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.010"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30311-1"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1085142"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.173039"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.055"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101563"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.11-0689"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.02.058"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.10.097"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7030071"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006870"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf7447"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2851"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.12.009"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918809117"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020093"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12670"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.183012"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.03.037"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30512-7"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1627205"},{"key":"e_1_3_4_126_1","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.4103\/ijph.IJPH_367_19","article-title":"Facilities and services of postexposure prophylaxis in anti-rabies clinics: A national assessment in India","volume":"63","author":"Sudarshan MK","year":"2019","unstructured":"Sudarshan MK, Haradanhalli RS. Facilities and services of postexposure prophylaxis in anti-rabies clinics: A national assessment in India. Indian J Public Health. 2019;63(Supplement):S26\u2013S30.","journal-title":"Indian J Public Health"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006387"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.043"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209946"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2020.01.008"},{"issue":"1","key":"e_1_3_4_131_1","article-title":"Reviewing solutions of scale for canine rabies elimination in India","volume":"5","author":"Gibson AD","year":"2020","unstructured":"Gibson AD, Wallace RM, Rahman A, et al. Reviewing solutions of scale for canine rabies elimination in India. Trop Med Infect Dis. 2020 Mar 23;5(1):21.","journal-title":"Trop Med Infect Dis"},{"key":"e_1_3_4_132_1","unstructured":"World Health Organization. 2020 April 21 [cited 2020 May 1]. Addressing human rights as key to the COVID-19 response. Geneva (Switzerland): WHO. https:\/\/www.who.int\/publications-detail\/addressing-human-rights-as-key-to-the-covid-19-response"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2020.1766021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:40:21Z","timestamp":1770403221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2020.1766021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":130,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1080\/14712598.2020.1766021"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2020.1766021","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}